TNXP Tonix Pharmaceuticals Holding Corp Forecast, Technical & Fundamental Analysis
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases... Show more
TNXP is expected to report earnings to -246 cents per share on November 09
Q3'26
Est.
$-2.46
Q2'26
Beat
by $0.27
Q1'26
Missed
by $0.35
Q4'25
Missed
by $0.79
Q3'25
Est.
$-3.59
The last earnings report on August 10 showed earnings per share of -244 cents, beating the estimate of -271 cents. With 250.82K shares outstanding, the current market capitalization sits at 215.25M.
A.I. Advisor
published General Information
General Information
a company which engages in developing and manufacturing pharmaceuticals
A.I.dvisor indicates that over the last year, TNXP has been closely correlated with ICU. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if TNXP jumps, then ICU could also see price increases.
TNXP saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for TNXP moved out of overbought territory on August 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 38 similar instances where the indicator exited the overbought zone. In of the 38 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNXP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TNXP broke above its upper Bollinger Band on August 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TNXP entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on TNXP as a result. In of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TNXP just turned positive on August 04, 2026. Looking at past instances where TNXP's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .
TNXP moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TNXP crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TNXP advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.968) is normal, around the industry mean (20.145). P/E Ratio (0.054) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.513) is also within normal values, averaging (444.692).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
